Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| V940-001 | Other Identifier | MSD | |
| 2023-503652-27-00 | Registry Identifier | EU CT | |
| jRCT2041230169 | Registry Identifier | jRCT | |
| U1111-1287-6366 | Registry Identifier | UTN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ModernaTX, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intismeran autogene + Pembrolizumab | Experimental | Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner. |
|
| Placebo + Pembrolizumab | Active Comparator | Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intismeran autogene | Biological | IM injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence-Free Survival (RFS) | RFS is defined as the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause. | Up to approximately 74 months |
| Measure | Description | Time Frame |
|---|---|---|
| Distant Metastasis-Free Survival (DMFS) | DMFS is the length of time from when the participant starts the study until either the cancer spreads from where it started to other parts of the body as assessed by the investigator, or death due to any cause. | Up to approximately 85 months |
| Overall-Survival (OS) |
Not provided
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Highlands Oncology Group ( Site 1943) | Springdale | Arkansas | 72762 | United States | ||
| UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918) |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
| Plain Language Summary | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double blind
| Pembrolizumab | Biological | IV infusion |
|
|
| Placebo | Other | IM injection |
|
|
OS is the length of time that people are alive after joining the study. |
| Up to approximately 85 months |
| Number of Participants Who Experience an Adverse Event (AE) | An AE is a health problem that happens or worsens during a study. Number of participants who experience an AE will be reported. | Up to approximately 68 weeks |
| Number of Participants Who Discontinue Study Treatment Due to an AE | An AE is a health problem that happens or worsens during a study. Number of participants who discontinue study treatment will be reported. | Up to approximately 56 weeks |
| Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score | The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better overall health status. Per protocol, the change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented. | Baseline and up to approximately 85 months |
| Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 | The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better level of physical functioning. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented. | Baseline and up to approximately 85 months |
| Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30 | The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a more impaired level of role functioning. Change from baseline in the role functioning (EORTC QLQ-C30 Items 6-7) combined score will be presented. | Baseline and up to approximately 85 months |
| Los Angeles |
| California |
| 90095 |
| United States |
| UCSF Medical Center at Mission Bay ( Site 1929) | San Francisco | California | 94158 | United States |
| Yale-New Haven Hospital-Yale Cancer Center ( Site 1933) | New Haven | Connecticut | 06510 | United States |
| Orlando Health Cancer Institute ( Site 1937) | Orlando | Florida | 32806 | United States |
| Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945) | Tampa | Florida | 33612 | United States |
| Winship Cancer Institute of Emory University ( Site 1940) | Atlanta | Georgia | 30322 | United States |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950) | Marietta | Georgia | 30060 | United States |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 1935) | Iowa City | Iowa | 52242 | United States |
| Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912) | Baltimore | Maryland | 21287 | United States |
| Massachusetts General Hospital ( Site 1927) | Boston | Massachusetts | 02114 | United States |
| Beth Israel Deaconess Medical Center ( Site 1957) | Boston | Massachusetts | 02215 | United States |
| Dana-Farber Cancer Institute ( Site 1956) | Boston | Massachusetts | 02215 | United States |
| University of Michigan ( Site 1915) | Ann Arbor | Michigan | 48109 | United States |
| Cancer and Hematology Centers of Western Michigan ( Site 1932) | Grand Rapids | Michigan | 49503 | United States |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944) | Hackensack | New Jersey | 07601 | United States |
| Atlantic Health System ( Site 1925) | Morristown | New Jersey | 07960 | United States |
| Valley Health Systems - Ridgewood Campus ( Site 1947) | Ridgewood | New Jersey | 07450 | United States |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958) | Mineola | New York | 11501 | United States |
| NYU Langone Health-Perlmutter Cancer Center ( Site 1917) | New York | New York | 10016 | United States |
| Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 1908) | New York | New York | 10032 | United States |
| Memorial Sloan Kettering Cancer Center ( Site 1914) | New York | New York | 10065 | United States |
| University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949) | Chapel Hill | North Carolina | 27599 | United States |
| Duke Cancer Institute ( Site 1911) | Durham | North Carolina | 27710 | United States |
| Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905) | Philadelphia | Pennsylvania | 19104 | United States |
| UPMC Hillman Cancer Center ( Site 1909) | Pittsburgh | Pennsylvania | 15232 | United States |
| Medical University of South Carolina-Hollings Cancer Center ( Site 1934) | Charleston | South Carolina | 29425 | United States |
| Sanford Cancer Center ( Site 1951) | Sioux Falls | South Dakota | 57104 | United States |
| SCRI Oncology Partners ( Site 1910) | Nashville | Tennessee | 37203 | United States |
| Texas Oncology - Austin ( Site 1903) | Austin | Texas | 78731 | United States |
| Texas Oncology - Dallas (Sammons) ( Site 1902) | Dallas | Texas | 75246 | United States |
| University of Texas MD Anderson Cancer Center ( Site 1920) | Houston | Texas | 77030 | United States |
| Inova Schar Cancer Institute ( Site 1900) | Fairfax | Virginia | 22031 | United States |
| Fred Hutchinson Cancer Center ( Site 1901) | Seattle | Washington | 98109 | United States |
| Clinica Adventista Belgrano-Oncology ( Site 2204) | Caba. | Buenos Aires | C1430EGF | Argentina |
| Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202) | Ciudad Autonoma de Buenos Aires | Buenos Aires | C1199ABB | Argentina |
| Instituto Alexander Fleming-Alexander Fleming ( Site 2203) | Buenos Aires | Buenos Aires F.D. | 1426ANZ | Argentina |
| Centro Privado de RMI Río Cuarto S.A. II ( Site 2201) | Río Cuarto | Córdoba Province | X5800ALB | Argentina |
| Hospital Aleman ( Site 2200) | Buenos Aires | C1118AAT | Argentina |
| Sanatorio Finochietto ( Site 2205) | Buenos Aires | C1187AAN | Argentina |
| Westmead Hospital ( Site 1001) | Westmead | New South Wales | 2145 | Australia |
| Melanoma Institute Australia-Clinical Trials Unit ( Site 1000) | Wollstonecraft | New South Wales | 2065 | Australia |
| Princess Alexandra Hospital ( Site 1003) | Brisbane | Queensland | 4102 | Australia |
| Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1005) | Melbourne | Victoria | 3000 | Australia |
| Paula Fox Melanoma & Cancer Centre ( Site 1004) | Melbourne | Victoria | 3004 | Australia |
| One Clinical Research ( Site 1002) | Nedlands | Western Australia | 6009 | Australia |
| UZ Brussel-Medische oncologie ( Site 3405) | Brussels | Bruxelles-Capitale, Region de | 1090 | Belgium |
| Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3402) | Genk | Limburg | 3600 | Belgium |
| UZ Gent ( Site 3403) | Ghent | Oost-Vlaanderen | 9000 | Belgium |
| UZ Leuven ( Site 3400) | Leuven | Vlaams-Brabant | 3000 | Belgium |
| AZ Groeninge Campus Kennedylaan-Oncology ( Site 3401) | Kortrijk | West-Vlaanderen | 8500 | Belgium |
| Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 2303) | Belo Horizonte | Minas Gerais | 30130-090 | Brazil |
| ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 2302) | Ijuí | Rio Grande do Sul | 98700-000 | Brazil |
| Hospital Nossa Senhora da Conceição ( Site 2309) | Porto Alegre | Rio Grande do Sul | 91350-200 | Brazil |
| Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC II ( Site 2305) | Rio de Janeiro | 20220-410 | Brazil |
| ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300) | São Paulo | 01246-000 | Brazil |
| Cross Cancer Institute ( Site 1104) | Edmonton | Alberta | T6G 1Z2 | Canada |
| BC Cancer Vancouver-Clinical Trials Unit ( Site 1106) | Vancouver | British Columbia | V5Z 4E6 | Canada |
| William Osler Health System ( Site 1105) | Brampton | Ontario | L6R 3J7 | Canada |
| Sunnybrook Research Institute ( Site 1103) | Toronto | Ontario | M4N 3M5 | Canada |
| Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 1102) | Toronto | Ontario | M5G 2M9 | Canada |
| Centre Hospitalier de l'Université de Montréal-Unité de Recherche Clinique en Oncologie et Hématolo ( Site 1100) | Montreal | Quebec | H2X 0X9 | Canada |
| Centre intégré de cancérologie du CHU de Québec Université L-Hemato-Oncology ( Site 1101) | Québec | Quebec | G1J 1Z4 | Canada |
| FALP-UIDO ( Site 2400) | Santiago | Region M. de Santiago | 7500921 | Chile |
| Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 2402) | Santiago | Region M. de Santiago | 7620002 | Chile |
| Bradfordhill ( Site 2401) | Santiago | Region M. de Santiago | 8420383 | Chile |
| Clinica Somer-Unidad de Investigacion y Docencia ( Site 2506) | Rionegro | Antioquia | 054040 | Colombia |
| Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2500) | Bogotá | Bogota D.C. | 111321 | Colombia |
| IMAT S.A.S ( Site 2503) | Montería | Departamento de Córdoba | 230002 | Colombia |
| Fundación Valle del Lili ( Site 2505) | Cali | Valle del Cauca Department | 760032 | Colombia |
| Herlev and Gentofte Hospital ( Site 3301) | Copenhagen | Capital Region | 2730 | Denmark |
| Aalborg Universitetshospital, Syd ( Site 3302) | Aalborg | North Denmark | 9000 | Denmark |
| Odense Universitetshospital ( Site 3300) | Odense C | Region Syddanmark | 5000 | Denmark |
| Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 1211) | Nice | Alpes-Maritimes | 06200 | France |
| Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi ( Site 1203) | Marseille | Bouches-du-Rhone | 13385 | France |
| Centre Georges François Leclerc ( Site 1210) | Dijon | Cote-d Or | 21079 | France |
| CHU Besançon ( Site 1209) | Besançon | Doubs | 25030 | France |
| CHU de Bordeaux Hop St ANDRE-Service de Dermatologie ( Site 1204) | Bordeaux | Gironde | 33075 | France |
| Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1206) | Rennes | Ille-et-Vilaine | 35042 | France |
| Hopital Claude Huriez - CHU de Lille ( Site 1207) | Lille | Nord | 59037 | France |
| centre hospitalier lyon sud-Service de dermatologie ( Site 1202) | Pierre-Bénite | Rhone | 69310 | France |
| CHU d'Amiens-Picardie - Hôpital Sud-Dermatologie ( Site 1208) | Amiens | Somme | 80054 | France |
| Gustave Roussy-Dermatologie ( Site 1201) | Villejuif | Val-de-Marne | 94800 | France |
| Hôpital Saint-Louis ( Site 1200) | Paris | 75010 | France |
| Universitätsmedizin Mannheim ( Site 1305) | Mannheim | Baden-Wurttemberg | 68167 | Germany |
| Universitaetsklinikum Augsburg ( Site 1312) | Augsburg | Bavaria | 86156 | Germany |
| Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 1315) | München | Bavaria | 80337 | Germany |
| Universitätsmedizin Göttingen - Georg-August-Universität-Dermatology ( Site 1308) | Göttingen | Lower Saxony | 37075 | Germany |
| Universitätsmedizin Rostock-Klinik und Poliklinik für Dermatologie und Venerologie ( Site 1310) | Rostock | Mecklenburg-Vorpommern | 18057 | Germany |
| Universitaetsklinikum Koeln ( Site 1307) | Cologne | North Rhine-Westphalia | 50937 | Germany |
| Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 1300) | Essen | North Rhine-Westphalia | 45147 | Germany |
| Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 1301) | Minden | North Rhine-Westphalia | 32429 | Germany |
| Universitaetsklinikum des Saarlandes ( Site 1313) | Homburg | Saarland | 66424 | Germany |
| SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1306) | Gera | Thuringia | 07548 | Germany |
| Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 1302) | Berlin | 10115 | Germany |
| Universitaetsklinikum Hamburg-Eppendorf ( Site 1309) | Hamburg | 20246 | Germany |
| General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 3700) | Athens | Attica | 115 26 | Greece |
| Metropolitan Hospital-A' Oncology Dpt ( Site 3701) | Neo Faliro | Attica | 185 47 | Greece |
| Bioclinic Thessalonikis Private Clinic Single Member S.A.-Oncology ( Site 3703) | Thessaloniki | Central Macedonia | 546 22 | Greece |
| European Interbalkan Medical Center-Oncology Department ( Site 3702) | Thessaloniki | 570 01 | Greece |
| Emek Medical Center ( Site 2003) | Afula | 1834111 | Israel |
| Hadassah Medical Center ( Site 2004) | Jerusalem | 9112001 | Israel |
| Rabin Medical Center ( Site 2000) | Petah Tikva | 4941492 | Israel |
| Sheba Medical Center ( Site 2001) | Ramat Gan | 5265601 | Israel |
| Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401) | Milan | Lombardy | 20133 | Italy |
| Istituto Europeo di Oncologia IRCCS ( Site 1404) | Milan | Lombardy | 20141 | Italy |
| Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 1402) | Siena | Tuscany | 53100 | Italy |
| AO Santa Maria della Misericordia ( Site 1403) | Perugia | Umbria | 06129 | Italy |
| Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi ( Site 1400) | Naples | 80131 | Italy |
| Nagoya University Hospital ( Site 4201) | Nagoya | Aichi-ken | 466-8560 | Japan |
| Shizuoka Cancer Center ( Site 4202) | Nagaizumi-cho,Sunto-gun | Shizuoka | 411-8777 | Japan |
| National Cancer Center Hospital ( Site 4200) | Chūō | Tokyo | 104-0045 | Japan |
| Capital, Coast and Hutt Valley District - Wellington Regional Hospital ( Site 1502) | Newtown | Wellington Region | 6021 | New Zealand |
| Harbour Cancer & Wellness ( Site 1500) | Auckland | 1023 | New Zealand |
| Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2909) | Poznan | Greater Poland Voivodeship | 60-569 | Poland |
| Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2908) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | 85-796 | Poland |
| Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2903) | Siedlce | Masovian Voivodeship | 08-110 | Poland |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2900) | Warsaw | Masovian Voivodeship | 02-781 | Poland |
| Bialostockie Centrum Onkologii ( Site 2905) | Bialystok | Podlaskie Voivodeship | 15-027 | Poland |
| Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site 2906) | Gdansk | Pomeranian Voivodeship | 80-214 | Poland |
| Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2907) | Gliwice | Silesian Voivodeship | 44-101 | Poland |
| Zachodniopomorskie Centrum Onkologii ( Site 2904) | Szczecin | West Pomeranian Voivodeship | 71-730 | Poland |
| Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 2902) | Kielce | Świętokrzyskie Voivodeship | 25-734 | Poland |
| Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3601) | Lisbon | Lisbon District | 1099-023 | Portugal |
| Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3602) | Lisbon | 1449-005 | Portugal |
| Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3603) | Lisbon | 1649-035 | Portugal |
| Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3604) | Porto | 4200-072 | Portugal |
| Medical Oncology Centre of Rosebank ( Site 4106) | Johannesburg | Gauteng | 2196 | South Africa |
| Wilgers Oncology Centre ( Site 4103) | Pretoria | Gauteng | 0040 | South Africa |
| Cape Town Oncology Trials ( Site 4100) | Cape Town | Western Cape | 7570 | South Africa |
| Kyungpook National University Chilgok Hospital-Hematology/oncology ( Site 3904) | Daegu | Taegu-Kwangyokshi | 41404 | South Korea |
| Chungnam national university hospital-Department of Internal Medicine ( Site 3903) | Daejeon | Taejon-Kwangyokshi | 35015 | South Korea |
| Seoul National University Hospital-Oncology ( Site 3902) | Seoul | 03080 | South Korea |
| Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3901) | Seoul | 03722 | South Korea |
| Samsung Medical Center-Division of Hematology/Oncology ( Site 3900) | Seoul | 06351 | South Korea |
| HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 1600) | Barcelona | Catalonia | 08036 | Spain |
| HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1603) | Pozuelo de Alarcón | Madrid | 28223 | Spain |
| Hospital Universitario Ramón y Cajal ( Site 1602) | Madrid | Madrid, Comunidad de | 28034 | Spain |
| H.R.U Málaga - Hospital General-Oncology ( Site 1605) | Málaga | Malaga | 29011 | Spain |
| HOSPITAL CLINICO DE VALENCIA ( Site 1604) | Valencia | Valenciana, Comunitat | 46010 | Spain |
| Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1601) | Barcelona | 08035 | Spain |
| Skånes Universitetssjukhus Lund ( Site 3201) | Lund | Skåne County | 22185 | Sweden |
| Sahlgrenska Universitetssjukhuset ( Site 3200) | Gothenburg | Västra Götaland County | 413 45 | Sweden |
| UniversitätsSpital Zürich-Dermatology ( Site 1700) | Zürich Flughafen | Canton of Zurich | 8058 | Switzerland |
| Kantonsspital Graubünden-Medizin ( Site 1703) | Chur | Kanton Graubünden | 7000 | Switzerland |
| Chang Gung Memorial Hospital at Kaohsiung ( Site 4000) | Kaohsiung City | 83301 | Taiwan |
| National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004) | Tainan | 704 | Taiwan |
| National Taiwan University Hospital ( Site 4001) | Taipei | 10002 | Taiwan |
| Chang Gung Medical Foundation-Linkou Branch ( Site 4003) | Taoyuan | 33305 | Taiwan |
| Hacettepe Universite Hastaneleri ( Site 3006) | Ankara | 06230 | Turkey (Türkiye) |
| Memorial Ankara Hastanesi-Medical Oncology ( Site 3010) | Ankara | 06520 | Turkey (Türkiye) |
| Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3002) | Ankara | 06800 | Turkey (Türkiye) |
| Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 3008) | Istanbul | 34303 | Turkey (Türkiye) |
| TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3003) | Istanbul | 34722 | Turkey (Türkiye) |
| Ege University Medical Faculty Hospital ( Site 3011) | Izmir | 35100 | Turkey (Türkiye) |
| I.E.U. Medical Point Hastanesi-Oncology ( Site 3005) | Izmir | 35575 | Turkey (Türkiye) |
| Bristol Haematology and Oncology Centre ( Site 1811) | Bristol | Bristol, City of | BS2 8ED | United Kingdom |
| Addenbrooke's Hospital ( Site 1800) | Cambridge | Cambridgeshire | CB2 2QQ | United Kingdom |
| Norfolk and Norwich University Hospitals NHS Foundation Trust ( Site 1813) | Cringleford | England | NR4 7UY | United Kingdom |
| University College London Hospital ( Site 1807) | London | London, City of | NW1 2PG | United Kingdom |
| ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1804) | London | London, City of | SW3 6JJ | United Kingdom |
| Western General Hospital ( Site 1806) | Edinburgh | Midlothian | EH4 2XU | United Kingdom |
| The Churchill Hospital ( Site 1805) | Oxford | Oxfordshire | OX3 7LE | United Kingdom |
| St James's University Hospital-Leeds Cancer Centre ( Site 1808) | Leeds | LS9 7TF | United Kingdom |
| The Christie NHS Foundation Trust ( Site 1814) | Manchester | m20 4bx | United Kingdom |
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C582435 | pembrolizumab |
| D000077330 | Saline Solution |
| D005947 | Glucose |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
| D006601 | Hexoses |
| D009005 | Monosaccharides |
| D000073893 | Sugars |
| D002241 | Carbohydrates |
Not provided
Not provided